English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Objective   The objective of this study was to investigate the expression of telomere repeat binding factor 1 (TRF1) and TRF2 in prostate cancer and their relationships with clinicopathological features.Methods   In total 50 prostate cancer tissues and paired benign prostate hyperplasia tissues were analyzed. The telomere-binding proteins TRF1 and TRF2 were measured using immunohistochemical method. Correlation analyses were used to evaluate the association between immunohistochemical score and clinical parameters.Results   The expression of TRF1 was significantly higher in prostate cancer tissue than in benign prostate hyperplasia tissue ( χ  2  = 62.69,  P  < 0.01). Elevated levels of TRF2 were observed in both prostate cancer and benign prostate hyperplasia tissue ( χ  2  = 1.13,  P  = 0.76). TRF1 expression was significantly positively correlated with surgical capsular invasion (Spearman's  r  = 0.43,  P  = 0.002), seminal vesicle invasion (Spearman's  r  = 0.35,  P  = 0.01), lymph nodes metastases (Spearman's  r  = 0.41,  P  = 0.003), total prostate specific antigen ( r  = 0.61,  P  < 0.05), and Gleason score ( r  = 0.47,  P  = 0.01). However, there were no significant statistical differences between prostate volume ( r  = 0.06,  P  = 0.75) and age ( r  = 0.14,  P  = 0.09).Conclusion   Both TRF1 and TRF2 were overexpressed in prostate cancer. There was no specificity of TRF2 in prostate cancer, while TRF1 may be associated with prostate cancer progression.

Expression of Telomere Repeat Binding Factor 1 and TRF2 in Prostate Cancer and Correlation with Clinical Parameters